ProPhase Labs to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

Rhea-AI Summary

ProPhase Labs (Nasdaq: PRPH) announces that CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand for registered attendees starting at 7:00 a.m. ET on January 10.

ProPhase Labs is a diversified biotech company focusing on genomics and CLIA lab services, including COVID-19 testing, whole genome sequencing, and genetic research.

GARDEN CITY, NY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, to H.C. Wainwright registered attendees of the conference.

Register for the conference here: https://hcwevents.com/bioconnect/

About ProPhase Labs

ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

ProPhase Diagnostics offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients who may have SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Critical to COVID testing, results are provided in under 24 hours. ProPhase Diagnostics also offers PCR (polymerase chain reaction) testing for Influenzas A and B as well as antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Global Healthcare, Inc. was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements^® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When is the ProPhase Labs presentation at the H.C. Wainwright Bioconnect 2022 Virtual Conference?

The ProPhase Labs presentation is scheduled for January 10-13, 2022.

What time will the ProPhase Labs presentation be available?

The presentation will be available on-demand starting at 7:00 a.m. ET on January 10, 2022.

What is the main focus of ProPhase Labs?

ProPhase Labs focuses on biotech, genomics, and providing CLIA lab services, including COVID-19 testing.

How can I register for the H.C. Wainwright Bioconnect 2022 Virtual Conference?

You can register for the conference on the H.C. Wainwright website.

What services does ProPhase Labs provide?

ProPhase Labs offers whole genome sequencing, COVID-19 testing, and various clinical diagnostic services.